Voya Investment Management LLC Reduces Holdings in STERIS plc $STE

Voya Investment Management LLC lowered its position in STERIS plc (NYSE:STE) by 22.5% in the 3rd quarter, HoldingsChannel reports. The fund owned 21,956 shares of the medical equipment provider’s stock after selling 6,358 shares during the period. Voya Investment Management LLC’s holdings in STERIS were worth $5,433,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of STE. Spurstone Advisory Services LLC bought a new position in STERIS in the 2nd quarter worth approximately $29,000. Geneos Wealth Management Inc. raised its stake in shares of STERIS by 416.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 104 shares during the period. Loomis Sayles & Co. L P bought a new stake in shares of STERIS during the 2nd quarter valued at $54,000. Generali Investments Management Co LLC purchased a new stake in STERIS during the 2nd quarter worth about $56,000. Finally, CYBER HORNET ETFs LLC bought a new position in STERIS in the 2nd quarter worth about $62,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Insider Activity

In other news, VP John Adam Zangerle sold 15,000 shares of the company’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total transaction of $3,977,100.00. Following the transaction, the vice president directly owned 33,669 shares of the company’s stock, valued at $8,926,998.66. This represents a 30.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Julia Madsen sold 5,008 shares of STERIS stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $262.00, for a total transaction of $1,312,096.00. Following the completion of the sale, the vice president directly owned 10,710 shares of the company’s stock, valued at approximately $2,806,020. This trade represents a 31.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 25,203 shares of company stock worth $6,624,667. Corporate insiders own 1.07% of the company’s stock.

STERIS Price Performance

STE stock opened at $255.68 on Thursday. The firm has a market cap of $25.09 billion, a P/E ratio of 36.74 and a beta of 1.01. The firm’s fifty day moving average is $253.68 and its 200 day moving average is $244.40. STERIS plc has a 52 week low of $200.98 and a 52 week high of $268.60. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.63 and a current ratio of 2.37.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.09. STERIS had a net margin of 12.07% and a return on equity of 14.43%. The firm had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter in the previous year, the company earned $2.14 earnings per share. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Research analysts predict that STERIS plc will post 9.08 earnings per share for the current year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th were paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Tuesday, November 18th. STERIS’s dividend payout ratio is currently 36.21%.

Wall Street Analysts Forecast Growth

STE has been the subject of a number of analyst reports. Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, STERIS presently has an average rating of “Moderate Buy” and an average price target of $273.50.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.